Blood Samples Collected to Study Liver Cancer Detection Tests
Collects blood from people with liver cancer or liver cirrhosis to study a blood test.
Key facts
- Who runs it
- Helio Genomics
- Where
- Edinburg, El Paso, Escondido, Gainesville, Mission Hills, Tampa, and Waco, United StatesSee the 7 sites
- Trial code
- Registry title
- Multi-analyte Blood Test Clinical Trial
- Status
- Recruiting
- People taking part
- 1,200 people, planned
- Started
- 1 Mar 2022
- Expected to end
- Dec 2028
- Type of study
- Observational, 3 groups
- Treatments tested
- Multi-analyte Blood Test
- Record updated
- 10 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis or at risk of liver cancer. Some have untreated hepatocellular carcinoma (HCC), and some have no HCC after screening. Blood samples are collected to develop a blood test.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Either a recent diagnosis (within 6 months) of untreated HCC, or no HCC confirmed by negative imaging within 3 months. People need cirrhosis or must meet AASLD guidelines for HCC surveillance. No more than 200 people without cirrhosis can join the HCC-negative group.
- Earlier treatment
- Cannot have had any treatment for HCC before joining, such as surgery, ablation, embolization or drug treatment. No chemotherapy or radiation therapy within 5 years.
Main reasons for not taking part
- Another cancer in the past 5 years (except basal cell or squamous cell skin cancer)
- Any earlier HCC treatment, including sorafenib or regorafenib
- Earlier treatment with Vidaza (azacitidine) or Dacogen (decitabine)
- Pregnancy
- Unable or unwilling to sign the consent form
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Age 18 years or older
- Males and Females
- Having cirrhosis or meeting the AASLD guidelines for HCC
- surveillance
- Clinically diagnosed with HCC or negative for HCC following disease
- surveillance
- HCC positive Group: Subject has a recent (within 6 months of enrollment) clinically diagnosed, untreated hepatocellular carcinoma as defined by at least one ≥1 cm lesion exhibiting arterial phase hyperenhancement in combination with washout appearance and/or capsule by 4 phase CT scan or multiphase contrast enhanced MRI or biopsy is positive for HCC
- HCC negative Group: Non-cancer, at-risk subjects with chronic liver disease undergoing routine imaging surveillance for HCC, where the definitive lack of HCC within 3 months prior to enrollment has been verified by negative imaging, for HCC. No more than 200 subjects without cirrhosis can be enrolled in this group
- Sub-Group 1 (approximately 450 subjects) - negative by CT or MRI (No lesion, LR-1 or LR-2)
- Sub-Group 2 (approximately 450 subjects) - negative by ultrasound
Who cannot take part
- Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection
- Prior or current treatment with sorafenib, regorafenib, or other treatment indicated for HCC
- Prior treatment with a DNA methyltransferase inhibitor such as with Vidaza (azacitidine) or Dacogen (decitabine)
- Any HCC treatment prior to enrollment/blood sample collection (e.g., surgery, ablation, embolization, pharmacotherapy, radiotherapy, liver transplant or other treatment indicated for HCC)
- For HCC negative subjects, patients with a prior diagnosis of HCC are also excluded
- Known cancer diagnosis of a cancer other than HCC within the past 5 years (with the exceptions of basal cell or squamous cell skin cancers)
- Any condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk
- Subjects that are unwilling or unable to sign the Informed Consent Form will be excluded
- IV contrast (e.g., CT and MRI) within 1 day [or 24 hours] of blood collection
- Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection
- Less than 7 days between biopsy (other than FNA) of target pathology and blood collection
- Subjects that are pregnant will be exclude
Where in United States
- South Texas Research InstituteEdinburg, United StatesContact: Site ManagerTaking people
- Texas Gastro ResearchEl Paso, United StatesContact: Sub-ITaking people
- Gastroenterology and Liver InstituteEscondido, United StatesContact: Yuri Guzman, MATaking people
- UF Hepatology Research at CTRBGainesville, United StatesContact: Lauren Morelli, CCRCTaking people
- Providence Facey Medical FoundationMission Hills, United StatesContact: Clinical Research AssociateTaking people
- Guardian Angel Research CenterTampa, United StatesContact: Study CoordinatorTaking people
- Impact Research InstituteWaco, United StatesContact: Site ManagerTaking people
About the trial
What the trial wants to find out
The objective of this study is the acquisition of whole blood samples and serum samples from participants with untreated Hepatocellular Carcinoma (HCC) and subjects undergoing Hepatocellular Carcinoma (HCC) surveillance. These samples will be used for research purposes to develop and validate the Helio multi-analyte blood test.
The 3 groups in the trial
- HCC positive Group
Multi-analyte blood test screen in participants with a recent confirmed untreated diagnosis of HCC by CT scan, MRI or biopsy.
Treatment: Multi-analyte Blood Test
- HCC negative Group: Sub-Group 1
Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by CT or MRI (No lesion, LR-1 or LR-2)
Treatment: Multi-analyte Blood Test
- HCC negative Group: Sub-Group 2
Multi-analyte blood test screen in participants with a recent confirmed negative diagnosis of HCC by ultrasound. Participants will be scheduled for a 6 month visit (at least 5 months but no more 9 months form enrollment) for a confirmatory ultrasound.
Treatment: Multi-analyte Blood Test
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma
- Plain-language title
- Blood Samples Collected to Study Liver Cancer Detection TestsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 10 July 2026